

Encorafenib BEACON CRC

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects




Other adjustments



Encorafenib BEACON CRC

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gastrointestinal Cancers
Therapeutic Indication: Treatment of patients with mCRC with a BRAF V600E mutation, who have received prior systemic therapy
Experimental Arm: Encorafenib + Cetuximab
Control Arm: Either irinotecan or FOLFIRI with cetuximab

